Gene expression profiling for improved dissection of acute leukemia: a recently identified immature myeloid/T-lymphoid subgroup as an example.

[1]  Pu Zhang,et al.  Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. , 2007, Blood.

[2]  Bas J. Wouters,et al.  Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia , 2007, Leukemia.

[3]  B. Clurman,et al.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.

[4]  A. Ferrando,et al.  The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia , 2007, The Journal of experimental medicine.

[5]  Daniel G. Tenen,et al.  Transcription factors in myeloid development: balancing differentiation with transformation , 2007, Nature Reviews Immunology.

[6]  M. Caligiuri,et al.  Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias , 2006, Leukemia.

[7]  Bas J. Wouters,et al.  Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. , 2006, Cancer cell.

[8]  T. Graf,et al.  Reprogramming of committed T cell progenitors to macrophages and dendritic cells by C/EBP alpha and PU.1 transcription factors. , 2006, Immunity.

[9]  Hideaki Nakajima,et al.  Comprehensive analysis of myeloid lineage conversion using mice expressing an inducible form of C/EBPα , 2006, The EMBO journal.

[10]  C. Plass,et al.  Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. , 2006, Journal of the National Cancer Institute.

[11]  A. Karsan,et al.  Recent insights into the role of Notch signaling in tumorigenesis. , 2006, Blood.

[12]  L. Bullinger,et al.  Gene expression profiling in acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Pu Zhang,et al.  Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. , 2004, Immunity.

[14]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[15]  T. Graf,et al.  Stepwise Reprogramming of B Cells into Macrophages , 2004, Cell.

[16]  C. Nerlov.  C/EBPα mutations in acute myeloid leukaemias , 2004, Nature Reviews Cancer.

[17]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[18]  E. Estey,et al.  Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. , 2004, American journal of clinical pathology.

[19]  S. Fröhling,et al.  CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Kwong,et al.  Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia , 2002, British journal of haematology.

[21]  C. Craddock,et al.  The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. , 2002, Cancer research.

[22]  B. Leber,et al.  CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform , 2001, American journal of hematology.

[23]  Pu Zhang,et al.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia , 2001, Nature Genetics.

[24]  J. Sklar,et al.  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles , 1996, The Journal of experimental medicine.

[25]  A. Hagemeijer,et al.  Acute myeloid leukemias with chromosomal abnormalities involving the 21q22 region identified by their in vitro responsiveness to interleukin-5. , 1991, Leukemia.

[26]  Bob Löwenberg,et al.  Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.

[27]  J. V. van Dongen,et al.  Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. , 1992, Leukemia.